Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Brignone · SciRah

Researcher profile · Semantic Scholar

C. Brignone

Share profile

C. Brignone — researcher profile on SciRah

h-index: 17
Works: 39
Citations: 2,417

Most-cited papers

Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300
S. Grossman, M. Deato, C. Brignone, Ho-Man Chan +4 more
2003Science526 citations
Semantic Scholar
Yin Yang 1 is a negative regulator of p53.
Guang-Chao Sui, E. Affar, Y. Shi, C. Brignone +7 more
2004Cell458 citations Open access
Semantic Scholar
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
C. Brignone, M. Gutiérrez, F. Mefti, E. Brain +8 more
2010Journal of Translational Medicine245 citations Open access
Semantic Scholar
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
P. Hémon, F. Jean-Louis, K. Ramgolam, C. Brignone +7 more
2011Journal of Immunology241 citations
Semantic Scholar
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
C. Brignone, B. Escudier, C. Grygar, M. Marcu +1 more
2009Clinical Cancer Research213 citations Open access
Semantic Scholar
Recruitment of the Actin-binding Protein HIP-55 to the Immunological Synapse Regulates T Cell Receptor Signaling and Endocytosis*
S. Le Bras, I. Foucault, A. Foussat, C. Brignone +2 more
2004Journal of Biological Chemistry98 citations Open access
Semantic Scholar
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
V. Atkinson, A. Khattak, A. Haydon, M. Eastgate +5 more
2020Journal for ImmunoTherapy of Cancer81 citations Open access
Semantic Scholar
A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway
C. Brignone, Kathleen Bradley, A. Kisselev, S. Grossman
2004Oncogene81 citations Open access
Semantic Scholar
A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells
C. Brignone, C. Grygar, M. Marcu, K. Schäkel +1 more
2007Journal of Immunology73 citations
Semantic Scholar
A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321.
S. Fougeray, C. Brignone, F. Triebel
2006Vaccine54 citations
Semantic Scholar
A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases
M. Angin, C. Brignone, F. Triebel
2020Journal of Immunology46 citations Open access
Semantic Scholar
IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study.
C. Brignone, C. Grygar, M. Marcu, G. Perrin +1 more
2007Vaccine43 citations
Semantic Scholar
Journal of Immune Based Therapies and Vaccines Imp321 (slag-3), an Immunopotentiator for T Cell Responses against a Hbsag Antigen in Healthy Adults: a Single Blind Randomised Controlled Phase I Study
C. Brignone, C. Grygar, M. Marcu, G. Perrin +1 more
39 citations
Semantic Scholar
Antibody‐mediated depletion of lymphocyte‐activation gene‐3 (LAG‐3+)‐activated T lymphocytes prevents delayed‐type hypersensitivity in non‐human primates
N. Poirier, Thomas Haudebourg, C. Brignone, N. Dilek +7 more
2011Clinical and Experimental Immunology38 citations Open access
Semantic Scholar
Binding of anti-CD23 monoclonal antibody to the leucine zipper motif of FcepsilonRII/CD23 on B cell membrane promotes its proteolytic cleavage. Evidence for an effect on the oligomer/monomer equilibrium.
O. Munoz, C. Brignone, N. Grenier‐Brossette, J. Bonnefoy +1 more
1998Journal of Biological Chemistry22 citations Open access
Semantic Scholar
Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma.
Martin Forster, I. Braña, Antonio Lopez Pousa, B. Doger +9 more
2024Clinical Cancer Research18 citations Open access
Semantic Scholar
Proteases produced by activated neutrophils release soluble CD23 fragments endowed with proinflammatory effects
C. Brignone, O. Munoz, M. Batoz, Alexandre K. Rouquette-Jazdanian +1 more
2001The FASEB Journal18 citations
Semantic Scholar
Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.
F. Duhoux, A. Jager, L. Dirix, M. Huizing +7 more
201817 citations
Semantic Scholar
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
H. Wildiers, A. Armstrong, Eveline Cuypere, F. Dalenc +16 more
2023Clinical Cancer Research16 citations Open access
Semantic Scholar
Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.
M. Eastgate, V. Atkinson, M. Khattak, A. Roy +5 more
201814 citations
Semantic Scholar
Binding of Anti-CD23 Monoclonal Antibody to the Leucine Zipper Motif of FcεRII/CD23 on B Cell Membrane Promotes Its Proteolytic Cleavage
O. Munoz, C. Brignone, N. Grenier‐Brossette, J. Bonnefoy +1 more
1998Journal of Biological Chemistry14 citations Open access
Semantic Scholar
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
S. Al-Batran, D. W. Mueller, Rafiyan, D. Kiselicki +11 more
2023ESMO Open12 citations Open access
Semantic Scholar
Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to Immunostimulant Drugs
Ya Wang, B. Gloss, B. Tang, S. Dervish +12 more
2021Frontiers in Immunology10 citations Open access
Semantic Scholar
Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II.
F. Duhoux, A. Jager, L. Dirix, M. Huizing +7 more
201710 citations
Semantic Scholar
Abstract PD14-08: Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
H. Wildiers, A. Armstrong, Eveline Cuypere, F. Dalenc +15 more
20217 citations
Semantic Scholar
790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)
M. Krebs, M. Majem, E. Felip, M. Forster +10 more
20204 citations Open access
Semantic Scholar
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study
M. Majem, E. Carcereny, B. Doger, Tim Clay +13 more
2025JCO Oncology Advances3 citations Open access
Semantic Scholar
1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)
W. Iams, E. Felip, M. Majem, B. Doger +16 more
2022Late-Breaking Abstracts3 citations Open access
Semantic Scholar
IMP321 and weekly paclitaxel as first-line chemoimmunotherapy for metastatic breast cancer (MBC)
F. Triebel, C. Brignone, C. Grygar, M. Marcu +1 more
20083 citations
Semantic Scholar
171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer
F. Marmé, H. Wildiers, L. Dirix, A. Armstrong +10 more
2022Annals of Oncology2 citations Open access
Semantic Scholar
948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC
H. Wildiers, L. Dirix, A. Armstrong, E. de Cuypere +13 more
2021Journal for ImmunoTherapy of Cancer2 citations Open access
Semantic Scholar
1033P The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumours
S. Al-Batran, D. Müller, Rafiyan, D. Kiselicki +5 more
20202 citations Open access
Semantic Scholar
DOP07 IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases
M. Angin, C. Brignone, F. Triebel
2019Journal of Crohn's & Colitis2 citations Open access
Semantic Scholar
Pharmacokinetic and Biological Correlative Study of IMP 321 , a Novel MHC Class II Agonist , in Patients with Advanced Renal Cell Carcinoma
C. Brignone, B. Escudier, C. Grygar, M. Marcu +1 more
20092 citations
Semantic Scholar
First-line chemoimmunotherapy in metastatic breast carcinoma: Effect of a combination of paclitaxel and LAG-3-ig (IMP321), a novel MHC class II agonist, on T-cell responses and antitumor activity.
M. Gutiérrez, C. Brignone, F. Mefti, F. Triebel
20101 citations
Semantic Scholar
Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.
Martin Forster, F. Forget, Serafin Morales Murillo, I. García-Fructuoso +13 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
M. Forster, E. Felip, M. Majem, B. Doger +14 more
2023Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
Resistance to Apoptosis LAG-3 (CD223) Contributes to Melanoma MHC Class II Engagement by Its Ligand
P. Hémon, F. Jean-Louis, K. Ramgolam, C. Brignone +7 more
20110 citations
Semantic Scholar
Large Range of Human Effector Cytotoxic Gene-3 ( IMP 321 ) Induces Activation of a A Soluble Form of Lymphocyte Activation
C. Brignone, C. Grygar, M. Marcu, K. Schaekel +1 more
20070 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Triebel×24
Invite
F. Triebel — researcher profile on SciRah
C. Mueller×9
Invite
C. Mueller — researcher profile on SciRah
C. Grygar×8
Invite
C. Grygar — researcher profile on SciRah
M. Marcu×8
Invite
M. Marcu — researcher profile on SciRah

×6

Invite

F. Triebel — researcher profile on SciRah

Invite

C. Mueller — researcher profile on SciRah

Invite

B. Doger — researcher profile on SciRah

E. Carcereny×5

Invite

E. Carcereny — researcher profile on SciRah

Invite

L. Dirix — researcher profile on SciRah

P. Vuylsteke×5

Invite

P. Vuylsteke — researcher profile on SciRah

E. de Cuypere×4

Invite

E. de Cuypere — researcher profile on SciRah

Invite

H. Wildiers — researcher profile on SciRah